Related Experiment Video
Updated: Jan 20, 2026

Therapy Testing in a Spheroid-based 3D Cell Culture Model for Head and Neck Squamous Cell Carcinoma
Published on: April 20, 2018
Glutaminolysis-related genes determine sensitivity to xCT-targeted therapy in head and neck squamous cell carcinoma
Shogo Okazaki1,2, Kiyoko Umene1,3, Juntaro Yamasaki1
1Division of Gene Regulation, Institute for Advanced Medical Research, School of Medicine, Keio University, Tokyo, Japan.
Abstract:
Targeting the function of membrane transporters in cancer stemlike cells is a potential new therapeutic approach. Cystine-glutamate antiporter xCT expressed in CD44 variant (CD44v)-expressing cancer cells contributes to the resistance to oxidative stress as well as cancer therapy through promoting glutathione (GSH)-mediated antioxidant defense. Amino acid transport by xCT might, thus, be a promising target for cancer treatment, whereas the determination factors for cancer cell sensitivity to xCT-targeted therapy remain unclear. Here, we demonstrate that high expression of xCT and glutamine transporter ASCT2 is correlated with undifferentiated status and diminished along with cell differentiation in head and neck squamous cell carcinoma (HNSCC). The cytotoxicity of the xCT inhibitor sulfasalazine relies on ASCT2-dependent glutamine uptake and glutamate dehydrogenase (GLUD)-mediated α-ketoglutarate (α-KG) production. Metabolome analysis revealed that sulfasalazine treatment triggers the increase of glutamate-derived tricarboxylic acid cycle intermediate α-KG, in addition to the decrease of cysteine and GSH content. Furthermore, ablation of GLUD markedly reduced the sulfasalazine cytotoxicity in CD44v-expressing stemlike HNSCC cells. Thus, xCT inhibition by sulfasalazine leads to the impairment of GSH synthesis and enhancement of mitochondrial metabolism, leading to reactive oxygen species (ROS) generation and, thereby, triggers oxidative damage. Our findings establish a rationale for the use of glutamine metabolism (glutaminolysis)-related genes, including ASCT2 and GLUD, as biomarkers to predict the efficacy of xCT-targeted therapy for heterogeneous HNSCC tumors.
Insights
Targeting cystine-glutamate antiporter xCT with sulfasalazine shows promise for head and neck cancer. Its efficacy depends on ASCT2 and GLUD, impacting glutathione synthesis and oxidative stress.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Metabolism
Background:
- Cancer stem-like cells exhibit resistance to therapy via mechanisms like oxidative stress.
- The cystine-glutamate antiporter xCT is crucial for glutathione synthesis and antioxidant defense in cancer cells.
- Understanding factors determining sensitivity to xCT-targeted therapy is vital for effective cancer treatment.
Purpose of the Study:
- To investigate the role of xCT and ASCT2 in head and neck squamous cell carcinoma (HNSCC) differentiation and therapy response.
- To elucidate the mechanism of sulfasalazine cytotoxicity in HNSCC.
- To identify biomarkers for predicting efficacy of xCT-targeted therapy.
Main Methods:
- Analysis of xCT and ASCT2 expression in HNSCC.
- Assessment of sulfasalazine cytotoxicity in relation to ASCT2 and GLUD.
- Metabolome analysis to study metabolic alterations upon sulfasalazine treatment.
- Gene ablation studies (GLUD) to confirm functional roles.
Main Results:
- High expression of xCT and ASCT2 correlates with undifferentiated HNSCC and decreases with differentiation.
- Sulfasalazine cytotoxicity is dependent on ASCT2-mediated glutamine uptake and GLUD-driven α-ketoglutarate production.
- Sulfasalazine treatment reduces cysteine and GSH levels while increasing α-ketoglutarate, leading to ROS generation and oxidative damage.
- GLUD ablation significantly reduces sulfasalazine's cytotoxicity in CD44v-expressing HNSCC cells.
Conclusions:
- Sulfasalazine-induced xCT inhibition impairs GSH synthesis and enhances mitochondrial metabolism, causing oxidative damage.
- ASCT2 and GLUD are critical for sulfasalazine efficacy in HNSCC.
- Glutamine metabolism-related genes (ASCT2, GLUD) can serve as biomarkers for predicting xCT-targeted therapy response in HNSCC.
Related Concept Videos
Arteries of the Head and Neck
The internal carotid arteries supply blood to the anterior portion of the cerebrum. They enter the...
Veins of Head and Neck
On the other hand, the vertebral veins, unlike their arterial counterparts, are not primarily responsible for brain drainage. Instead, they drain the cervical vertebrae, spinal cord, and some small...
Gene Therapy
Targeted Cancer Therapies
There are several types of targeted therapies against...
Muscles of the Anterior Neck
Cell Specific Gene Expression

